Background-Cervicovaginal HIV level (CV-VL) influences HIV transmission. Plasma viral load (PVL) correlates with CV-VL but discordance is frequent. We evaluated how PVL, behavioral, immunologic and local factors/conditions individually and collectively correlate with CV-VL.
Introduction
Worldwide, 33.4 million people are infected with human immunodeficiency virus type 1 (HIV) with an estimated 2.7 million new infections yearly. 1 Most infections are acquired sexually or perinatally. Higher plasma viral load (PVL) correlates with increased likelihood of sexual and perinatal transmission, while antiretroviral treatment (ART), in particular highly active antiretroviral therapy (HAART), correlates with reduced transmission. [2] [3] [4] [5] HIV presence in the female genital tract is important in perinatal 4 and sexual transmission. 6 Increased cervicovaginal HIV level (CV-VL) likely increases risk of transmucosal HIV passage during penile-vaginal intercourse and vaginal delivery.
The quantity of HIV in the female genital tract correlates with various factors, including PVL, 7 immune status, 8 cervicovaginal inflammation, 9 and ART. 10;11 HIV characteristics, including tropism and resistance pattern, can differ markedly in different compartments, including the female genital tract, 12;13 male genital tract, 14 and central nervous system. 15;16 HIV can be detected in cell-free and cell-associated components of cervicovaginal fluid. 17 Local conditions in the female genital tract including inflammation, 18 bacterial vaginosis, 19 cervical ectopy, 20 genital ulceration, 18 candidiasis, 21 HSV, 22 trichomoniasis, 20 and other infections influence cervicovaginal HIV shedding. Menstrual cycle phase 23;24 and hormonal contraception 25 may affect shedding. ART, in particular HAART, is associated with decreased cervicovaginal HIV shedding. 11;26 Discordance between HIV presence in the bloodstream and cervicovaginal shedding is frequent. HIV can be present in the genital tract despite undetectable PVL, suggesting local replication. 27;28 Factors that may cause increased cervicovaginal shedding due to local replication include poor penetration of antiretrovirals into genital secretions, 29 local resistance, 13 and local inflammation. 28 Conversely, HIV is sometimes absent from genital secretions despite high PVL, suggesting that additional factors may be necessary to permit shedding.
While previous studies have shown association between numerous conditions and cervicovaginal HIV shedding, the mechanisms for presence and level of HIV in the cervicovaginal compartment are not well understood. 28 Several studies have evaluated the variation in cervicovaginal HIV shedding over various time-periods, particularly the possible influence of the menstrual cycle. 23;24;30;31 However, the frequencies and determinants of different temporal patterns of cervicovaginal HIV shedding have not been fully characterized. The purpose of this study is to evaluate how behavioral, therapeutic, clinical, immunologic and local factors correlate, individually and collectively, with cervicovaginal HIV shedding, at single time-points and as a longitudinal pattern.
in cervicovaginal lavage fluid (CVL) at least once as part of several WIHS substudies between 11/9/1994 and 9/12/2001 were included in this study. 7;33 Clinical Data WIHS methods have been described. 32 At baseline and each semiannual visit, subject history, including health information, medications including antiretrovirals, sexual history, substance use and other behavioral data were obtained using a standardized interview. Physical and gynecological examinations were performed. Blood and gynecological specimens were collected for local testing and repository storage. Genital tract assessment included visual inspection, speculum, and sometimes bimanual and rectal examination. Cervical lesions (ulcers, vesicles, fissures, or warts), ectopy ("beefy" redness extending from os onto cervix), friability (erythematous tissue that bleeds easily), exudate (discharge of any type) were ascertained visually. CVL was collected by spraying 10 mL of sterile, nonbacteriostatic saline against the cervical os and endocervix and aspirating from the posterior vaginal fornix. Unfractionated CVL was stored at −70°C.
Laboratory Data
Blood analyses included complete blood count, lymphocyte subsets, and plasma HIV RNA (PVL). We determined lymphocyte subsets with standard flow cytometric techniques at local laboratories. Baseline serology for HSV-1, HSV-2 and syphilis screening were performed with Western Blot and rapid plasma reagin (RPR) test respectively in a central laboratory. 32 Baseline HCV antibody testing was performed by Abbott enzyme immunoassays (version 2.0 or 3.0). HCV RNA levels were measured in a single laboratory (University of Southern California) by polymerase chain reaction (Roche Diagnostics). 34 Baseline hepatitis B profile was also performed in local laboratories.
We collected whole blood for PVL determination in sodium citrate cell preparation tubes. Plasma HIV quantitation was completed in four central laboratories. Initially, PVL was measured with a nucleic acid sequence-based amplification technique (Organon Teknika Corp, Durham, NC), with lower threshold of detection of 4000 copies/mL. Similar methods with greater sensitivity were used as they became available. WIHS currently uses the NucliSens (Organon Teknika Corp) assay for quantification of HIV RNA in plasma with a lower limit of detection (LLD) of 80 copies/mL with 1 mL of sample input. In general, at the beginning of the study period (visits 1-7), PVL had an LLD of 4000 copies/mL, while for visits 7-9 it improved to 400 copies/mL, and from visit 10 onward to 80 copies/mL. HIV quantitation in CVL (CV-VL) used the NucliSens assay (LLD of 80 copies/mL). However, these changes occurred in the laboratories at different times.
Cervicovaginal specimens included vaginal swabs for pH, potassium hydroxide preparation, candida culture, saline preparation for microscopy, Gram stain, swabs for HSV culture if cervical/vaginal ulcer, fissure, or vesicle present, syphilis if ulcer/fissure/vesicle(s) present, endocervical swabs for gonorrhea/chlamydia nucleic acid detection tests and trichomonas culture, and a Papanicolaou (Pap) smear. CVL was tested for microsopic blood and semen. Pap smears were read in a central laboratory (Kyto Diagnostics New York, N.Y.). Squamous metaplasia (replacement of one normal type of epithelium with another), endocervical cells, inflammation (leukocytes on Pap smear), and inflammation-associated cellular changes (cellular changes found with inflammation including basophilic cytoplasm, enlarged unevenly-sized nuclei, enlarged, irregular or multiple nucleoli, repair) were ascertained from Pap smear. Gram stains were interpreted for bacterial vaginosis (BV) in a central laboratory (University of Washington) using the Nugent score criteria, with categorization as normal (0-3), intermediate (4) (5) (6) , or consistent(7-10). 35 Trichomoniasis was diagnosed if motile trichomonads were present on wet mount or with positive culture. Candidiasis was diagnosed by pseudohyphae presence on potassium hydroxide preparation or positive culture. PCR to identify 29 types of humanpapillomavirus (HPV) was performed in central laboratories. 36 We analyzed separately several high-risk types of HPV (16, 18, 31, 33, 35) .
Statistical Methods
Demographic covariates included age (categorized as <35, 35-40, 41+ ) and self-identified race/ethnicity (White, African-American, Hispanic, Other). HIV exposure category (intravenous drug use, heterosexual risk, transfusion risk, no identified risk, unknown) was specified. Behavioral covariates included current smoking (no, yes), current alcohol consumption (abstainer, <3, 3-13, ≥14 drinks/week), current injection drug use (no, yes), current use of other recreational substances (marijuana, cocaine, heroin, other), number of lifetime male sex partners (0-6, 7-29, 30+), number of male sex partners since last study visit (0, 1, 2+), and vaginal sex with male in past 48 hours (no, yes). Therapeutic, immunologic, and clinical covariates included type of ART used since last visit (none, monotherapy, combination therapy, HAART), hormonal contraceptive use in past 6 months (no, yes), PVL, CD4 cell count (≤200, 201-350, 351-500, and >500 cells/mm 3 ), prior history of an AIDS-defining illness, hepatitis C status at baseline (antibody negative, antibody positive/RNA negative, antibody positive/RNA positive), and seropositivity for HSV-1 and HSV-2. The definition of HAART was guided by the DHHS/Kaiser Panel 2008. 37 Local cervicovaginal covariates included vaginal pH (<4.5, 4.5-5.4, ≥5.5), abnormal Pap (no, yes), bacterial vaginosis score, 35 and presence of the following: friability, ectopy, exudate, lesions, candidiasis, Trichomonas vaginalis, endocervical cells, squamous metaplasia, cervicovaginal inflammation, inflammation-associated cellular changes, and HPV (all types, oncogenic types).
Individual visit analysis, level of shedding-This analytic approach correlated data from individual person-visits with level of CV-VL. To accommodate multiple visits per subject, regression models utilized generalized estimating equations with an exchangeable correlation matrix and an identity link function. The dependent variable for this linear regression model was log 10 CV-VL. Visits where the CV-VL was less than the LLD (80 copies/ml) were assigned a value of ½ LLD (40) . Visit-specific covariates were used from each visit at which CV-VL was measured. Plasma HIV RNA was analyzed both as categorical (≤4000, 4001-9999, 10000-39999, 40000-99999, ≥100,000 copies/mL), where ≤4000 copies/mL was modeled as the referent group, and as a log 10 -transformed continuous variable, where values less than the LLD for the assay used were assigned a numeric value of ½LLD. Factors were evaluated in unadjusted and multivariate models. The multivariate model retained factors associated with CV-VL in unadjusted analyses at P<0.10 that remained at P<0.10. Associations were summarized as β-coefficients with associated standard errors. Two-sided hypotheses were assessed at the 5% significance level. Finally, we stratified person-visits into groups with detectable (≥80 copies/ml) and undetectable (<80 copies/ml) PVL and performed similar analyses on these strata to determine shedding associations with PVL detectable or undetectable. Person-visits with undetectable PVL when LLD was 400 copies/mL (n=24) and 4000 copies/mL (n=10) were excluded from this analysis.
In order to better understand the role of cervicovaginal inflammation as a condition in shedding we devised a tool to assess the presence/absence of any cervicovaginal inflammatory condition associated with shedding. We defined a binary variable, called inflammation summary variable (ISV), to have the value "1" if any local inflammatory factor significantly associated with CV-VL on univariate analysis was present (inflammation-associated cellular changes, cervical ectopy, exudate, friability, lesions, vaginal pH >5.5, intermediate BV score, consistent BV score, trichomoniasis) and "0" if none was present. Using this variable, we used Fisher's exact test to evaluate for interaction between PVL detectability and inflammation (by ISV value) in correlation with shedding presence ( Table 2 ). We used the generalized estimating equation to test for interaction between cervicovaginal inflammation and PVL in correlation with CV-VL.
Analysis of longitudinal shedding pattern-This analytic approach categorized
subjects into three groups to evaluate the pattern of cervicovaginal shedding over a series of visits. Categories were defined as follows: "never shedder" if a subject had no visits at which HIV was detected in cervicovaginal secretions, "intermittent shedder" if she had shedding at one or two visits, "persistent shedder" if she had shedding at three or more visits. Shedding category was assigned a three-level variable (coded 0, 1, 2) corresponding to never, intermittent and persistent shedding, respectively. For uniformity, this analysis was restricted to all subjects with at least three visits over a three-year period where at most one semiannual visit could be missed between evaluable visits. Data included visits from 3/31/1998-9/12/2001. Independent variables were the same as in the individual visit analysis, but taken from the first evaluable visit. PVL was analyzed as a categoric variable (≤400, 401-3999, 4000-19999, and ≥20000 copies/mL) and as a log 10 -transformed continuous variable, where values less than the LLD for a particular assay were assigned a numeric value of ½ LLD. Summary variables were created to characterize the pattern of HAART use (none, intermittent, always) and PVL detection (always, sometimes, never) over the evaluated visits. Initial unadjusted analyses were performed using ordinal logistic regression followed by multivariate analyses, using all factors with P<0.10 in univariate analysis, controlling for type of ART (none, non-HAART, HAART) and PVL category. Similarly, unadjusted analyses and analyses adjusting for initial PVL were performed on the subgroup of patients with "always-detectable PVL," but not on the "sometimes" and "neverdetectable" groups, due to insufficient cases of persistent shedding (2/50 and 0/24, respectively).
Results

Study Population
481 women had a total of 976 visits at which genital shedding was evaluated. Baseline demographic and clinical characteristics of the study population are summarized in Table 1 . The median number of person-visits was 1. 31% had 3 or more person-visits. The median age at baseline was 36.3 years. 52% of women were African American and 33% Hispanic. 29.6% had baseline plasma viral load below 4000 copies/mL (median=16,000 copies/mL), while 25.5% had CD4 ≥ 500 cells/mm 3 . Tobacco use was reported at 38% of person-visits. Hormonal contraception was reported at 6% of person-visits. The distribution of risky behaviors included: heavy alcohol use, 11%, injection drug use, 36.5%, and >30 lifetime sex partners, 35.9%. Few women had evidence of chlamydia, 0.2%, gonorrhea, 0%, or active HSV at baseline, 0.2%. HSV seropositivity was common, HSV-1: 83%; HSV-2: 77%. 17.2% had a positive screening test for syphilis (RPR). Other cervicovaginal infections present at baseline included trichomoniasis, 11.8%, HPV (all types) 52.7%, bacterial vaginosis (Nugent score 7-10) 47.1%. The percentage of participants receiving HAART increased from 0.3% at the initial visit where shedding was measured to 70% by the last visit of the study period.
Discordance between PVL and CV-VL
Subgroups of person-visits stratified with respect to PVL, CV-VL, cervicovaginal inflammation and antiretroviral therapy are shown in Table 2 . Discordance between PVL and CV-VL occurred in 47% of person-visits. In 959 person-visits with measured PVL, 45.3% had detectable PVL/undetectable CV-VL, 32.6% detectable PVL/detectable CV-VL, 20.4% undetectable PVL and CV-VL, and 1.6% had undetectable PVL/detectable CVL. Significant inflammation, expressed by the "inflammation summary variable," was present in 76.5% and absent at 23.5% of evaluable person-visits (n=958). CV-VL was detectable in 37.4% of person-visits at which inflammation was present (ISV=1) and 24% at which it was absent (ISV=0). When PVL was detectable, CV-VL was detectable in 264/587 (44.9%) of person-visits with inflammation presence and 48/160 (30%) with absence. In the sub-group with PVL≥80 (LLD=80), shedding was significantly more likely with inflammation present (ISV=1) (P=0.003). Table 3 shows variables associated with CV-VL level at individual person-visits. In multivariate analysis, higher CV-VL correlated significantly with higher PVL (β=0.50 per log 10 copies/mL; P <0.001), cervical inflammation-associated cellular changes (β=0.38; P=0.03), ectopy (β=0.48; P=0.009), exudate (β=0.18; P=0.005), and trichomoniasis (β=0.31; P=0.03). Lower CV-VL correlated with HAART use (β=−0.17; P=0.01). CV-VL did not correlate with hormonal contraception use. The inflammatory summary variable correlated with increased CV-VL in univariate analysis (β=0.29; P<0.001), and in a separate multivariate model with log 10 HIV-RNA and antiretroviral therapy (β=0.16; P=0.004). PVL had significant interaction with the inflammation summary variable in correlating with CV-VL (interaction coefficient 0.26, P=0.006). Multivariate analysis (Table 4 ) of the PVLdetectable stratum (n=665) showed strong correlation between higher CV-VL and PVL (for >100,000 copies/mL β=0.80; P<0.001), friability (β=0.23; P=0.05), ectopy (β=0.46; P=0.02) exudate (β=0.25; P=0.001), trichomoniasis (β=0.33; P=0.04), and inflammation-associated cellular changes (β=0.61; P=0.007). In multivariate analysis of the PVL-undetectable stratum (n=132 person-visits), cervicovaginal inflammatory conditions did not correlate with CV-VL. As expected, HAART correlated with decreased CV-VL (β=−0.39; P=0.04).
Factors associated with level of shedding at individual person-visits
Factors associated with pattern of genital shedding over multiple visits (Table 5)
Of 481 evaluable women, 136 (31%) had CVL-VL measured at 3 or more visits within a 3year period with a median of four evaluable visits (range: 3-6). The shedding distribution included: 40.4% (n=55) "never," 44.9% (n=61) "intermittent," and 14.7% (n=20) "persistent." Ordinal logistic regression adjusted for ART showed that a pattern of higher frequency of shedding over visits (i.e., intermittent/persistent vs. never; or persistent vs. intermittent/never) was associated with higher initial PVL (OR= 2.47 per log 10 copies/mL; P<0.01; Table 5 ). With adjustment for ART and PVL, higher shedding frequency also correlated with any alcohol use (OR=2.20; P=0.03) and seropositivity for HSV-2 (OR=3.21; P=0.009). Never detectable PVL correlated strongly with lower likelihood of higher shedding frequency (OR=0.10; P<0.001). Even in the subgroup with always detectable PVL, 18/62 (29%) had persistent shedding, but 20/62 (32%) never shed and 24/62 (39%) shed intermittently. In this subgroup, higher shedding frequency correlated with alcohol use (OR=4.92; P=0.003) and HSV-2 seropositivity (OR=4.44; P=0.04) ( Table 6 , supplemental digital content). Additionally in this subgroup, vaginal candidiasis correlated with a 15-fold increase in the odds of higher shedding frequency (OR=15.14; P=0.009).
Discussion
This study comprehensively assessed demographic, behavioral, clinical, therapeutic and local factors that correlate individually and collectively with level and pattern of HIV shedding in the female genital tract both at individual person-visits (cross-sectionally) and longitudinally. The two analytic approaches are complementary. The person-visit analysis elucidates the association between identified factors and CV-VL at individual time-points, while the longitudinal analysis clarifies how behaviors and conditions present at the initial visit, as well as summary variables measuring HAART adherence and PVL suppression over all visits, correlate with the temporal pattern of shedding. Subanalyses shed light on discordance between PVL and cervicovaginal HIV presence, level, and pattern.
As shown previously, 11;26;38 at individual person-visits PVL and HAART are the principal factors associated with CV-VL, correlating with higher and lower levels, respectively. Correlation between PVL and CV-VL may be direct, due to transmigration of cell-free or cell-associated HIV from the bloodstream, indirect, related to local replication responding to the same factors as systemic replication, or both. Similarly, HAART may influence CV-VL directly by reducing local replication, indirectly by reducing HIV bloodstream replication, or both. Consistent with previous studies, 18;39;40 local inflammatory conditions, diagnosed clinically, such as exudate, ectopy, friability, and presence of lesions, microbiologically, such as Trichomonas vaginalis, and histologically, such as inflammation-related cellular changes correlated significantly with increased shedding in the person-visit analysis.
How local inflammatory conditions lead to increased cervicovaginal HIV shedding is not well understood. There may be several mechanisms, and their order of importance may vary depending on circumstances. Cervicovaginal inflammation may increase vascular permeability, allowing HIV transmigration from bloodstream to cervicovaginal compartment. 18 Local inflammation may directly stimulate HIV replication, or lead to recruitment of HIV-producing leukocytes from adjacent lymphoid tissue. 22;39 When HIV is undetectable in the bloodstream, local replication, allowed by inadequate antiretroviral levels or resistance, may lead to detectable HIV in cervicovaginal secretions. Some authorities suggest that the source of most inflammation-associated cervicovaginal HIV is local replication. 18;39 There was significant discordance between PVL and CV-VL both at individual person-visits and as a pattern. Similar to previous studies, 28;41 CV-VL was detectable at 7.6% (15/211) of person-visits when PVL was undetectable. Surprisingly, CV-VL was undetectable at 58% (436/748) of person-visits when PVL was detectable. With detectable PVL, CV-VL correlated significantly with inflammatory conditions and PVL. Indeed, inflammation presence (ISV=1) led to increased correlation between PVL and CV-VL. This suggests that, when local inflammatory conditions are present, a significant amount of HIV in cervicovaginal secretions is due to transmigration from the bloodstream, rather than local replication, likely due to a compromised bloodstream-tissue barrier. However, even in the absence of cervicovaginal inflammation, CV-VL was sometimes detectable. Conversely, in the undetectable PVL stratum, increased shedding did not correlate with local inflammatory conditions. This suggests that, when antiretroviral suppression is effective, cervicovaginal inflammatory conditions are insufficient to cause shedding. HAART correlated with decreased CV-VL in the entire group and was the only factor to correlate with decreased CV-VL in the PVL-undetectable stratum. Though the main protective effect of HAART stems from PVL suppression, an additional protective effect may be suppression of cervicovaginal HIV replication, particularly when PVL is already low or undetectable. However, the number of person-visits with undetectable PVL was insufficient to draw reliable conclusions about all but very strong associations in this stratum.
In longitudinal analysis, even with always undetectable PVL, intermittent CVL shedding was sometimes present (5/24 subjects). Conversely, many subjects with always detectable PVL never had CVL HIV shedding (20/62 subjects). Persistent shedding in this group was associated with inflammatory factors such as HSV-2 seropositivity and vaginal candidiasis, as well as alcohol use. Thus, the longitudinal pattern of shedding correlates not only with HIV levels in the bloodstream, but also with factors leading to cervicovaginal inflammation.
Interestingly, we noted an association between alcohol use and shedding persistence. Association between alcohol use and cervicovaginal shedding was demonstrated in one previous study. 42 This is plausible, as alcohol affects HIV replication and susceptibility, causing increased SIV replication in animal models, 43 and increased HIV replication in PBMCs and susceptibility of CD4 lymphocytes to HIV infection in vitro. 44 No other behavior, including recent sexual intercourse, was associated with increased cervicovaginal shedding. Similar to previous studies, 45 HSV-2 seropositivity without overt lesions correlated with shedding persistence. This may be due to inflammation from low-grade HSV replication.
Our study has several limitations. An observational study, it cannot determine causation. During the study period there were major changes in HIV quantitation and treatment and resultant population health status. HIV levels in cervicovaginal secretions were measured in CVL, a semiquantitative method, rather than more precise means, such as cervical wick or swab. In addition, presence of intracellular integrated HIV-provirus was not evaluated, possibly leading to underestimation of HIV quantity in CVL.
Conclusions
Undetectable PVL due to effective HAART is strongly associated with reduced CV-VL, but does not assure shedding absence. 28 Conversely, cervicovaginal HIV shedding may be undetectable without antiretroviral therapy and with high PVL. When HIV is present in the bloodstream, "permissive" factors, conditions or behaviors associated with cervicovaginal inflammation, correlate with increased shedding. "Protective" factors include HAART and control of such conditions or behaviors. Therefore, prediction of cervicovaginal HIV shedding solely on the basis of ART and PVL is unreliable. As a practical matter, HIVinfected women should be counseled that cervicovaginal inflammatory conditions may increase risk of sexual transmission of HIV, and medical providers advised to diagnose and treat such conditions as a means of reducing HIV transmission. Serodiscordant couples with perfect HAART adherence and consistently undetectable PVL in the infected partner should be advised that while sexual transmission is unlikely, consistent condom use combined with HAART remains the most reliable means of prevention. 2;46 Further studies are needed to determine the source of HIV in cervicovaginal secretions, and factors that lead to shedding despite control of systemic replication.
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